Skip to main content

The Globe and Mail

9 top-selling drugs for ultra-rare diseases

A bioprocessing engineer shows a shaker flask where cells in growth medium are cultured in a laboratory at Dutch biotech company uniQurein in Amsterdam Dec. 13, 2012. The cells are being used as tiny factories to produce the gene therapy drug Glybera.


Rare diseases are a growing focus for drug companies, with prices for some treatments for ultra-rare conditions running into hundreds of thousands of dollars a year.

The following are among the top-selling treatments for extremely rare disorders:

Treatment for a progressive disease that destroys red blood cells and a second condition that damages the kidney and other vital organs.
Company: Alexion Pharmaceuticals (U.S.)
Forecast 2012 sales: $1.1 billion.

Story continues below advertisement

Helps break down fatty clumps that build up in cells in patients with Gaucher disease, damaging the liver, spleen and bones.
Company: Sanofi (France)
Forecast 2012 sales: $830 million

Treatment for Pompe disease, an inherited neuromuscular disorder that causes progressive muscle weakness.
Company: Sanofi (France)
Forecast 2012 sales: $580 million

Treatment for Hunter syndrome, a genetic disease that primarily affects males, causing serious physical and mental problems.
Company: Shire PLC (U.K.)
Forecast 2012 sales: $495 million

Treatment for Fabry disease; designed to counter damaging symptoms including kidney failure, heart problems and stroke.
Company: Sanofi (France)
Forecast 2012 sales: $352 million

Prevents dangerous swelling and painful attacks in people with hereditary angioedema.
Company: ViroPharma Inc. (U.S.)
Forecast 2012 sales: $330 million

Treatment for Gaucher disease.
Company: Shire PLC (U.K.)
Forecast 2012 sales: $310 million

Treats a rare form of the lung disease cystic fibrosis in patients with a particular genetic mutation.
Company: Vertex Pharmaceuticals Inc. (U.S.)
Forecast 2012 sales: $260 million

Story continues below advertisement

Treatment for Maroteaux-Lamy syndrome, which causes short stature, stiff joints and breathing problems.
Company: Biomarin Pharmaceutical Inc. (U.S.)
Forecast 2012 sales: $233 million

Source: Sales figures based on analyst forecasts compiled by Thomson Reuters

Report an error
As of December 20, 2017, we have temporarily removed commenting from our articles. We hope to have this resolved by the end of January 2018. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to If you want to write a letter to the editor, please forward to